AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20035187 — intervention group
Group type: COMPARATOR
Intervention: Patients without BM
Number of subjects: 1135
Study 17511363 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge needle
Number of subjects: 810
Study 17511363 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-gauge needle
Number of subjects: 810
Study 17511363 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-gauge needle
Number of subjects: 810
Study 17511363 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 810
Study 16187618 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide design (MCA)
Number of subjects: 10
Study 16187618 — intervention group
Group type: EXPERIMENTAL
Intervention: 1SR design (MCA)
Number of subjects: 10
Study 16187618 — intervention group
Group type: EXPERIMENTAL
Intervention: 2SR design (MCA)
Number of subjects: 10
Study 16187618 — intervention group
Group type: EXPERIMENTAL
Intervention: Thick design (MCA)
Number of subjects: 10
Study 12685514 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (Tra) 2 mg
Number of subjects: 92
Study 12685514 — intervention group
Group type: COMPARATOR
Intervention: Quinapril (Qui) 20 mg
Number of subjects: 92
Study 10073329 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS oxybutynin chloride 5 mg once daily for 4 days
Number of subjects: 13
Study 10073329 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release oxybutynin 5 mg every 8 hours for 4 days
Number of subjects: 13
Study 10073329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 13
Study 10073329 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS oxybutynin chloride
Number of subjects: 13
Study 8839195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high-dose streptokinase
Number of subjects: 77
Study 8839195 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose streptokinase
Number of subjects: 77
Study 14621759 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV-Polyglobulin (2 ml/kg body weight)
Number of subjects: 120
Study 14621759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraglobin (15 g)
Number of subjects: 120
Study 14621759 — intervention group
Group type: COMPARATOR
Intervention: No specific anti-CMV prophylaxis (Control group)
Number of subjects: 120
Study 3935486 — intervention group
Group type: EXPERIMENTAL
Intervention: 19NT-hexoxyphenylpropionate (19NT-HPP), 200 mg/week intramuscularly for 7 weeks
Number of subjects: 12
Study 3935486 — intervention group
Group type: EXPERIMENTAL
Intervention: 19NT-hexoxyphenylpropionate (19NT-HPP) given every 3 weeks
Number of subjects: 12
Study 31272399 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message support intervention (4 messages/week for 6 months)
Number of subjects: 160
Study 31272399 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 160
Study 29539274 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral regimen (fluconazole 1200 mg/day plus flucytosine 100 mg/kg/day for 2 weeks)
Number of subjects: 721
Study 29539274 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week amphotericin B (1 mg/kg/day)
Number of subjects: 721
Study 29539274 — intervention group
Group type: COMPARATOR
Intervention: 2-week amphotericin B (1 mg/kg/day)
Number of subjects: 721
Study 29539274 — intervention group
Group type: EXPERIMENTAL
Intervention: Flucytosine as partner drug with amphotericin B
Number of subjects: 721
Study 29539274 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week amphotericin B plus flucytosine
Number of subjects: 721
Study 30640987 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal fumigation combined with leflunomide (20 mg) and prednisone (15 mg) once per day for 6 months
Number of subjects: 99
Study 30640987 — intervention group
Group type: COMPARATOR
Intervention: Western drugs (leflunomide and prednisone)
Number of subjects: 99
Study 25007725 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intravenous (IV) and topical application of tranexamic acid (TXA): 1.5 g topical TXA + 1.5 g IV-TXA
Number of subjects: 184
Study 25007725 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tranexamic acid (IV-TXA): 3 g
Number of subjects: 184
Study 22505603 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 180 µg/m(2) with carprofen 4 mg/kg
Number of subjects: 100
Study 22505603 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 180 µg/m(2) with meloxicam 0.3 mg/kg
Number of subjects: 100
Study 22505603 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 6 mg/m(2) with carprofen 4 mg/kg
Number of subjects: 100
Study 22505603 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol 6 mg/m(2) with meloxicam 0.3 mg/kg
Number of subjects: 100
Study 20440550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness and yoga intervention (12-week duration)
Number of subjects: 97
Study 20440550 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 97
Study 17919272 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 33
Study 17919272 — intervention group
Group type: COMPARATOR
Intervention: Octreotide
Number of subjects: 33
Study 16041635 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water gavage drip (SWGD)
Number of subjects: 60
Study 16041635 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous fluid management
Number of subjects: 60
Study 12394909 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic brain stimulation after treadmill challenge (four stimuli per minute) until disappearance of symptoms
Number of subjects: 42
Study 12394909 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 subjects)
Number of subjects: 42
Study 10089845 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 50000
Study 10089845 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 50000
Study 10089845 — intervention group
Group type: COMPARATOR
Intervention: ICD usage
Number of subjects: 50000
Study 7751709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (10 mg/kg/day by continuous intravenous infusion)
Number of subjects: 56
Study 7751709 — intervention group
Group type: COMPARATOR
Intervention: Control (standard quinine regimen without pentoxifylline)
Number of subjects: 56
Study 7751709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 56
Study 7751709 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 1529900 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic low-risk identification procedure
Number of subjects: 195
Study 1529900 — intervention group
Group type: COMPARATOR
Intervention: Clinical low-risk identification procedure
Number of subjects: 195
Study 1529900 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined echocardiographic and clinical evaluations
Number of subjects: 195
Study 1529900 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic examination
Number of subjects: 195
Study 1529900 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic studies
Number of subjects: 195
Study 6363492 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene-hydrochlorothiazide
Number of subjects: 0
Study 6363492 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone-hydrochlorothiazide
Number of subjects: 0
Study 6363492 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 6363492 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study 30350477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.03 mg
Number of subjects: 17
Study 30350477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.08 mg
Number of subjects: 17
Study 30350477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.2 mg
Number of subjects: 17
Study 30350477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.6 mg
Number of subjects: 17
Study 30350477 — intervention group
Group type: COMPARATOR
Intervention: Commercial glucagon (Eli Lilly) 0.03 mg
Number of subjects: 17
Study 30350477 — intervention group
Group type: COMPARATOR
Intervention: Commercial glucagon (Eli Lilly) 0.08 mg
Number of subjects: 17
Study 30350477 — intervention group
Group type: COMPARATOR
Intervention: Commercial glucagon (Eli Lilly) 0.2 mg
Number of subjects: 17
Study 30350477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.03 mg in hypoglycaemia
Number of subjects: 17
Study 30350477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon 0.08 mg in hypoglycaemia
Number of subjects: 17
Study 30350477 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon (all doses)
Number of subjects: 17
Study 29223585 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice drink (BR; 55 mL)
Number of subjects: 10
Study 29223585 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-concentrated beetroot juice drink (BL; 456 mL)
Number of subjects: 10
Study 29223585 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid beetroot flapjack (BF; 60 g)
Number of subjects: 10
Study 29223585 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble beetroot crystals (BC; ∼1.40 mmol NO3‐)
Number of subjects: 10
Study 29223585 — intervention group
Group type: COMPARATOR
Intervention: Control drink (CON; 70 mL deionised water)
Number of subjects: 10
Study 27341973 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 33
Study 27341973 — intervention group
Group type: COMPARATOR
Intervention: Conventional Dry Dressings (CDD)
Number of subjects: 33
Study 24566875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressing a training device ( +  condition)
Number of subjects: 8
Study 24566875 — intervention group
Group type: COMPARATOR
Intervention: Keeping the hand quiet ( ‐ condition)
Number of subjects: 8
Study 23031570 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (1 MHz & 1.5 W/cm2) plus exercise
Number of subjects: 50
Study 23031570 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound plus exercise
Number of subjects: 50
Study 21211430 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion at 21 o'clock
Number of subjects: 111
Study 21211430 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid palatal expansion at 9 o'clock
Number of subjects: 111
Study 17286243 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (0 - 0 - 10 mg)
Number of subjects: 30
Study 17286243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 16119601 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane end‐tidal 2%
Number of subjects: 60
Study 16119601 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane end‐tidal 1.1%
Number of subjects: 60
Study 16119601 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 6 mg kg(‐1) h(‐1) in oxygen 33% and air
Number of subjects: 60
Study 11833666 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective rationing option (test B)
Number of subjects: 1184
Study 11833666 — intervention group
Group type: COMPARATOR
Intervention: Lottery selection for test B beneficiaries
Number of subjects: 1184
Study 11833666 — intervention group
Group type: COMPARATOR
Intervention: First-come-first-served selection for test B beneficiaries
Number of subjects: 1184
Study 11833666 — intervention group
Group type: COMPARATOR
Intervention: Medical associations selection for test B beneficiaries
Number of subjects: 1184
Study 10427382 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia (CSE)
Number of subjects: 80
Study 10427382 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EP)
Number of subjects: 80
Study 7646664 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician reminder letter and telephone contact
Number of subjects: 0
Study 7646664 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 2179283 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/ZOK 50 mg once daily for 4 weeks
Number of subjects: 98
Study 2179283 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/ZOK 50 mg daily
Number of subjects: 98
Study 2179283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 696981 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (Valium) 0.3 mg/kg
Number of subjects: 30
Study 696981 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 30
Study 29254116 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance expiratory muscle strength training (EMST)
Number of subjects: 42
Study 29254116 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (sham EMST device with no loading)
Number of subjects: 42
Study 25798748 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous urinary catheterization (CC)
Number of subjects: 123
Study 25798748 — intervention group
Group type: COMPARATOR
Intervention: Intermittent catheters (IC)
Number of subjects: 123
Study 23510189 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed group (n = 172)
Number of subjects: 332
Study 23510189 — intervention group
Group type: COMPARATOR
Intervention: Uninformed group (n = 160)
Number of subjects: 332
Study 23510189 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall agreement
Number of subjects: 332
Study 21145839 — intervention group
Group type: EXPERIMENTAL
Intervention: BI201335 20 mg once-daily for 14 days
Number of subjects: 34
Study 21145839 — intervention group
Group type: EXPERIMENTAL
Intervention: BI201335 48 mg once-daily for 14 days
Number of subjects: 34
Study 21145839 — intervention group
Group type: EXPERIMENTAL
Intervention: BI201335 120 mg once-daily for 14 days
Number of subjects: 34
Study 21145839 — intervention group
Group type: EXPERIMENTAL
Intervention: BI201335 240 mg once-daily for 14 days
Number of subjects: 34
Study 21145839 — intervention group
Group type: EXPERIMENTAL
Intervention: BI201335 48 mg once-daily with PegIFN/RBV for 28 days
Number of subjects: 34
Study 21145839 — intervention group
Group type: EXPERIMENTAL
Intervention: BI201335 120 mg once-daily with PegIFN/RBV for 28 days
Number of subjects: 34
Study 21145839 — intervention group
Group type: EXPERIMENTAL
Intervention: BI201335 240 mg once-daily with PegIFN/RBV for 28 days
Number of subjects: 34
Study 21145839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 19994683 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-needle-in-nape acupuncture (FNN)
Number of subjects: 60
Study 19994683 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture (RA)
Number of subjects: 60
Study 16770028 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Mitomycin C (0.01%)
Number of subjects: 28
Study 16770028 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 28
Study 15511682 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS) monotherapy initiated at 2mg/kg, increased to maintenance dosage of 8.0 mg/kg (mean, 7.97 +/- 0.55 mg/kg)
Number of subjects: 72
Study 15511682 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS) monotherapy
Number of subjects: 72
Study 15511682 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (ZNS) with carbamazepine (CBZ) added in 12 patients with uncontrolled seizures
Number of subjects: 72
Study 11354781 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE DD genotype
Number of subjects: 95
Study 11354781 — intervention group
Group type: COMPARATOR
Intervention: ACE ID or II genotype
Number of subjects: 95
Study 11354781 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hypertension
Number of subjects: 95
Study 11354781 — intervention group
Group type: EXPERIMENTAL
Intervention: Gross proteinuria
Number of subjects: 95
Study 9172045 — intervention group
Group type: EXPERIMENTAL
Intervention: CHG‐5 protocol (initial scrub of 5 min and consecutive scrubs of 3.5 min with chlorhexidine gluconate 4%)
Number of subjects: 23
Study 9172045 — intervention group
Group type: EXPERIMENTAL
Intervention: CHG‐3 protocol (initial scrub of 3 min and consecutive scrubs of 2.5 min with chlorhexidine gluconate 4%)
Number of subjects: 23
Study 9172045 — intervention group
Group type: EXPERIMENTAL
Intervention: PI‐3 protocol (initial scrub of 3 min and consecutive scrubs of 2.5 min with povidone iodine 5% and triclosan 1%)
Number of subjects: 23
Study 9172045 — intervention group
Group type: EXPERIMENTAL
Intervention: IPA protocol (initial scrub of 2 min with chlorhexidine gluconate 4% followed by isopropanol 70% and chlorhexidine gluconate 0.5%)
Number of subjects: 23
Study 9172045 — intervention group
Group type: EXPERIMENTAL
Intervention: EA protocol (initial scrub of 2 min with chlorhexidine gluconate 4% followed by ethanol 70% and chlorhexidine gluconate 0.5%)
Number of subjects: 23
Study 9172045 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-based antiseptics (IPA and EA)
Number of subjects: 23
Study 9172045 — intervention group
Group type: COMPARATOR
Intervention: Detergent-based antiseptics (CHG‐5, CHG‐3, PI‐3)
Number of subjects: 23
Study 8252111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine oestrogens, 0.625 mg daily, with cyclical oral dl-norgestrel, 0.15 mg daily
Number of subjects: 66
Study 8252111 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta-oestradiol, 0.05 mg daily, with cyclical transdermal norethisterone acetate, 0.25 mg daily
Number of subjects: 66
Study 3608343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100mg administered at 07.00 hours
Number of subjects: 8
Study 3608343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100mg administered at 13.00 hours
Number of subjects: 8
Study 3608343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100mg administered at 19.00 hours
Number of subjects: 8
Study 3608343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100mg administered at 01.00 hours
Number of subjects: 8
Study 29579503 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PIVO blood collections
Number of subjects: 160
Study 29579503 — intervention group
Group type: COMPARATOR
Intervention: Routine phlebotomy
Number of subjects: 160
Study 27544678 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 40
Study 27544678 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 40
Study 26278513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled pen (75 mg and 150 mg doses)
Number of subjects: 400
Study 26278513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe (75 mg and 150 mg doses)
Number of subjects: 400
Study 26278513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled pen
Number of subjects: 400
Study 26278513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled syringe
Number of subjects: 400
Study 26278513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled pen and syringe
Number of subjects: 400
Study 24016489 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 0
Study 24016489 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 0
Study 20026578 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance integrated health care programme (n = 11)
Number of subjects: 40
Study 20026578 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 16)
Number of subjects: 40
Study 18173308 — intervention group
Group type: EXPERIMENTAL
Intervention: 3DAC MR imaging on a 3-tesla system
Number of subjects: 33
Study 15738708 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Continuous Glucose Monitoring System (CGMS) sensor
Number of subjects: 200
Study 12957251 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT plus amifostine (300 mg/m² daily i.v. infusion)
Number of subjects: 73
Study 12957251 — intervention group
Group type: COMPARATOR
Intervention: RCT alone
Number of subjects: 73
Study 11235460 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed arthroscopic irrigation solution
Number of subjects: 24
Study 11235460 — intervention group
Group type: COMPARATOR
Intervention: Room-temperature irrigation solution
Number of subjects: 24
Study 8878577 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 12
Study 8878577 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin (8 to 12 mg/kg)
Number of subjects: 12
Study 8878577 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin (8 to 12 mg/kg)
Number of subjects: 12
Study 1521653 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase leuprolide acetate (LA) initiated pituitary down regulation followed by human menopausal gonadotropins (hMG)
Number of subjects: 408
Study 1521653 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) and human menopausal gonadotropins (hMG)
Number of subjects: 408
Study 6380347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (600 mg by mouth daily, increased to 1200 mg daily after one month)
Number of subjects: 128
Study 6380347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study 6380347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 128
Study 30612112 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 2-3 times/week during 4 months + lifestyle management
Number of subjects: 123
Study 30612112 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, 500 mg, three times/day during 4 months + lifestyle management
Number of subjects: 123
Study 30612112 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle management alone
Number of subjects: 123
Study 30062577 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (10, 20, and 30 mg/70 kg)
Number of subjects: 20
Study 30062577 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (400 mg/70 kg)
Number of subjects: 20
Study 30062577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26655430 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally targeted 12-week multimodal lifestyle intervention
Number of subjects: 22
Study 26655430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22